01
Identify & schedule
The care team identifies eligible patients and adds Mureva to the radiation care workflow
FOR CANCER CENTERS
Bring evidence-based PBM into routine radiation care
Mureva combines clinically meaningful outcomes with a standardized 10-minute treatment and a defined implementation pathway for radiation oncology clinicians and departments.
WHY ADDRESS OM DIFFERENTLY?
Oral mucositis affects more than the mouth
Radiation-induced oral mucositis can cause severe pain and make it difficult for patients to eat, drink, swallow, and speak. In many centers, management remains largely supportive after symptoms develop. Mureva gives radiation oncology teams an FDA-authorized option designed to lower severity and associated complications in indicated patients.
WHICH PATIENTS ARE ELIGIBLE?
The intended Mureva patient
Mureva is intended for indicated adult patients receiving head and neck radiation to less than 75% of the oral cavity, with or without chemotherapy. The treating team determines eligibility using the radiation treatment plan and the current Mureva instructions for use.
DAILY TREATMENT WORKFLOW
Mureva does not change the patient’s radiation delivery
02
Treat before RT
A trained team member delivers the standardized 10-minute Mureva treatment immediately before radiation therapy
03
Document & continue
Treatment completion is documented and the patient proceeds to the planned radiation treatment
BRING MUREVA TO YOUR CENTER
Operational requirements
Space
Defined Mureva location within/near radiation oncology. No capital construction required.
Staff
Trained personnel to prepare, supervise, document, and reprocess.
Scheduling
A repeatable daily appointment immediately before radiation.
Equipment
Light Control Unit, mouthpieces, validated reprocessing pathway.
Documentation
A consistent process for tracking, QA, and charge capture.
ARIA WORKFLOW FIT
Designed to work within familiar radiation oncology processes
Mureva can be implemented within existing ARIA workflows for scheduling, documentation, charge capture, and quality assurance. A site-specific workflow is established during implementation so the department can identify the right patient, deliver the right treatment, and document completion each day.
IMPLEMENTATION AND SUPPORT
From planning to first patient
VALUE ACROSS THE DEPARTMENT
Stakeholder-specific value
Radiation Oncologists
Nursing and Clinical Operations
Clinical Administration and Revenue Cycle
Infection Prevention and Sterile Processing
CLEANING AND REPROCESSING
A validated reprocessing pathway
Reusable and per-patient components are cleaned and reprocessed according to Mureva’s validated instructions for use. During implementation, Mureva works with infection prevention, sterile processing, nursing, and clinical operations to establish a site-specific process before go-live.
FIND OUT MORE
Frequently asked questions
The Mureva treatment itself is 10 minutes and is delivered immediately before radiation. Total operational time depends on the center’s setup, staffing, and reprocessing process.
No. The patient proceeds to the planned radiation treatment after Mureva therapy.
Yes. Mureva can be implemented within existing ARIA workflows for scheduling, treatment tracking, charge capture, and quality assurance.
The treating clinical team determines eligibility based on the radiation treatment plan, the authorized indication, and the current instructions for use.
Mureva supports readiness planning, workflow design, training, go-live, and ongoing clinical and operational questions.
Mureva is supported by a randomized, double-blind, sham-controlled pivotal trial published in Supportive Care in Cancer, which showed a significant reduction in severe oral mucositis with no device-related adverse events.
Mureva uses per-patient mouthpieces and a validated cleaning and reprocessing pathway. Device-specific instructions and implementation support are provided during setup.
A trained member of the radiation oncology team delivers the treatment under the care team’s supervision. It does not require the physician or physicist to administer.
MUREVA TRIAL SITES
Participating Pivotal Trial Sites
*Participating Pivotal research sites shown. Inclusion does not imply current commercial use or endorsement
Evaluate Mureva for your cancer center
A site evaluation helps your team work through eligible patient volume, workflow, staffing, reprocessing, and coding and coverage, and how patients will be identified, scheduled, and documented before treatment begins.